Invesco Solar ETF vs Viatris Inc — how do they compare? Invesco Solar ETF trades at $43.75 (market cap $894.08M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 22.4× Invesco Solar ETF's market cap, and Viatris Inc pays a 2.75% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 34 Days and Viatris Inc for 57 Days on average.
| TAN | VTRS | |
|---|---|---|
Market Cap | $894.08M | $20.03B |
Volume | 370,994 | 14,109,977 |
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $18.27 |
52-Week Low | $43.00 | $9.74 |
Typical Hold Time | 34 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
TAN trades at $43.32, down 0.48% amid broad solar sector weakness driven by high borrowing costs impacting project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from market saturation concerns and price deflation in the solar industry, though long-term growth prospects remain supported by global renewable energy transitions.
Outlook remains cautious due to persistent sector volatility and competitive pressures from lower-cost energy ETFs. Investment opportunity exists for long-term investors betting on solar adoption, but risks include interest rate sensitivity, regulatory uncertainty, and significant historical drawdowns exceeding 70%.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →